Thalidomide affects limb formation and multiple myeloma related genes in human induced pluripotent stem cells and their mesoderm differentiation

Shimizu, Maho; Tachikawa, Saoko; Saitoh, Nagatsuki; Nakazono, Kohei; Liu, Yujung; Suga, Mika; Ohnuma, Kiyoshi

doi:10.1016/j.bbrep.2021.100978

Cited by 2 publications

(1 citation statement)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Acetyl-CoA synthetase 2 (ACSS2; involved in β-oxidation) expression is increased in MM patients ( 67 ) and inhibition of β-oxidation with Etomoxir (a CPT1 inhibitor) and/or Orlistat (a Fatty acid synthase (FASN) inhibitor), decreased MM proliferation ( 68 ). Furthermore, the membrane transporter fatty acid binding protein (FABP) ( 69 , 70 ) as well as fatty acid import ( 55 , 71 ) are also increased in MM. Support of biosynthetic pathways appears to be another important function of the TCA cycle.…”

Section: Multiple Myeloma Metabolism and Its Involvement In Drug Resi...mentioning

confidence: 99%

Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

et al. 2023

View full text Add to dashboard Cite

Multiple myeloma (MM) is characterized by the clonal expansion of malignant plasma cells in the bone marrow (BM). MM remains an incurable disease, with the majority of patients experiencing multiple relapses from different drugs. The MM tumor microenvironment (TME) and in particular bone-marrow stromal cells (BMSCs) play a crucial role in the development of drug resistance. Metabolic reprogramming is emerging as a hallmark of cancer that can potentially be exploited for cancer treatment. Recent studies show that metabolism is further adjusted in MM cells during the development of drug resistance. However, little is known about the role of BMSCs in inducing metabolic changes that are associated with drug resistance. In this Perspective, we summarize current knowledge concerning the metabolic reprogramming of MM, with a focus on those changes associated with drug resistance to the proteasome inhibitor Bortezomib (BTZ). In addition, we present proof-of-concept fluxomics (glucose isotope-tracing) and Seahorse data to show that co-culture of MM cells with BMSCs skews the metabolic phenotype of MM cells towards a drug-resistant phenotype, with increased oxidative phosphorylation (OXPHOS), serine synthesis pathway (SSP), TCA cycle and glutathione (GSH) synthesis. Given the crucial role of BMSCs in conveying drug resistance, insights into the metabolic interaction between MM and BMSCs may ultimately aid in the identification of novel metabolic targets that can be exploited for therapy.

show abstract

Section: Multiple Myeloma Metabolism and Its Involvement In Drug Resi...mentioning

confidence: 99%

Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

et al. 2023

View full text Add to dashboard Cite

show abstract

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy

Zhang

Chang²,

Liu³

et al. 2022

Front. Oncol.

View full text Add to dashboard Cite

Hematological malignancies are one of the most lethal illnesses that seriously threaten human life and health. Lipids are important constituents of various biological membranes and substances for energy storage and cell signaling. Furthermore, lipids are critical in the normal physiological activities of cells. In the process of the lethal transformation of hematological malignancies, lipid metabolism reprogramming meets the material and energy requirements of rapidly proliferating and dividing tumor cells. A large number of studies have shown that dysregulated lipid metabolism, commonly occurs in hematological malignancies, mediating the proliferation, growth, migration, invasion, apoptosis, drug resistance and immune escape of tumor cells. Targeting the lipid metabolism pathway of hematological malignancies has become an effective therapeutic approach. This article reviews the oncogenic mechanisms of lipid metabolism reprogramming in hematological malignancies, including fatty acid, cholesterol and phospholipid metabolism, thereby offering an insight into targeting lipid metabolism in the treatment of hematological malignancies.

show abstract

Thalidomide affects limb formation and multiple myeloma related genes in human induced pluripotent stem cells and their mesoderm differentiation

Cited by 2 publications

References 45 publications

Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

Metabolic changes underlying drug resistance in the multiple myeloma tumor microenvironment

Reprogramming lipid metabolism as potential strategy for hematological malignancy therapy

Contact Info

Product

Resources

About